If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
GIP / GLP-1 dual receptor agonist
Batch documentation
Request the Tirzepatide batch COA and confirm the documentation required for your QA file, destination market, and proposed fill sizes before quotation.
Overview
For 503A patient-specific compounders and 503B outsourcing facilities, Tirzepatide arrives as a fully-characterised 39-residue GIP / GLP-1 balanced dual agonist API. The defining structural feature is a C20 fatty-diacid attached to a lysine side chain, which mediates reversible serum-albumin binding and locks in the once-weekly PK that separates this molecule from the earlier GLP-1 mono-agonist generation. The same active drives the FDA-approved finished products Mounjaro (T2DM) and Zepbound (chronic weight management); the API supplied here is the upstream feedstock, not a finished dosage form. Vialdyne releases lyophilised Tirzepatide acetate to a ≥99.0% HPLC main-peak specification area, with a batch COA reporting RP-HPLC peak integration and ESI-MS identity within 0.5 Da of the 4813.45 Da theoretical; Karl Fischer water determination and counter-ion quantitation are available on request and listed on the COA when tested. LAL endotoxin per USP <85>, microbial limits per USP <61>/<62>, and full LC-MS/MS sequence confirmation are available as documented add-ons on the same lot and are included only when required by a written buyer procedure and agreed before quotation. The fill ladder spans 5 mg to 120 mg across eleven nominal strengths so a single qualified supplier covers everything from pilot work to weekly dispensing inventory; sterile-filled presentations and pre-blended Tirzepatide + Cagrilintide co-lyophilisates can be arranged under a project-specific change-control with full ICH-Q1A stability commitment.
Applications & buyer fit
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Supplied as a documented active in acetate counter-ion form by default; the buyer verifies current scheduling and compounding eligibility for the destination market.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Nasal spray listing · US inventory
Tirzepatide is also listed in this catalog as a nasal spray solution.

Batch COAs and test reports
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COATirzepatide 2 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COATirzepatide 5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COATirzepatide 10 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COATirzepatide 15 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COATirzepatide 20 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COATirzepatide 30 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COATirzepatide 40 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COATirzepatide 50 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COATirzepatide 60 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COATirzepatide 80 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COATirzepatide 100 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COATirzepatide 120 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Browse all COAs and reportsRegulatory note
As a finished drug, Tirzepatide is FDA-approved and marketed under Mounjaro and Zepbound. What we supply, however, is the pharmaceutical-grade active for research and, where local rules allow, for formulation by compounding pharmacies. That active does not presently appear on the 503A bulks list. Whether it may be compounded turns on the destination market's shortage status and regulatory stance at the moment of dispensing, and confirming that at dispense time is the buyer's responsibility.
Selected literature
Frequently asked questions
The CAS Registry number is 2023788-19-2, molecular formula C225H348N48O68, average MW 4813.45 g/mol. Structurally it is a 39-amino-acid sequence carrying a C20 fatty-diacid albumin-binder on a lysine side chain. Every batch COA confirms identity by ESI-MS against the theoretical MW, and the full identity stack (sequence, CAS, formula, theoretical MW) is reproduced on the SDS.
Receptor scope is the headline difference: Semaglutide is a selective GLP-1 mono-agonist, whereas Tirzepatide is a balanced co-agonist of GIP and GLP-1 receptors. The backbone is also longer (39 residues vs 31), and the lipidation chemistry differs, Tirzepatide uses a C20 diacid, Semaglutide a C18 diacid, with related but distinct linker geometry. Both are dosed once-weekly because both rely on albumin-binding for half-life extension; the dual-receptor mechanism is what produces the larger HbA1c and body-weight reductions seen in head-to-head Phase 3 readouts.
Acetate is the standard counter-ion released from our process. Compounding pharmacies should default to acetate because residual TFA from older purification routes is documented to confound cell-based potency assays and is harder to clear from the final dosage form. TFA-salt material is available only on explicit written request with a documented downstream need, and the lot certificate will flag the counter-ion change for the pharmacy's QA file.
Eleven nominal strengths are catalogued: 5, 10, 15, 20, 30, 40, 50, 60, 80, 100, and 120 mg. The 5-20 mg fills are the workhorses for 503A patient-specific compounding because they map cleanly onto the typical reconstitution-and-aliquot worksheets; the 40-120 mg fills support 503B batch dispensing and weekly clinic inventory builds. Custom strengths, ISO-class sterile fills, and co-lyophilised Tirzepatide + Cagrilintide presentations are scoped under a separate change-control with stability commitment per ICH-Q1A.
Yes. Tirzepatide is listed as a nasal spray solution (5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg), filled in 10 mL or 20 mL bottles, with an MOQ of 10 bottles per content and fill. It is dispatched within the United States from US inventory; send an inquiry for current availability.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides
GLP-1 receptor agonist
Nasal spray listed
GIP / GLP-1 / glucagon tri-agonist
Nasal spray listedCapsules listed
Long-acting amylin analog
Nasal spray listed